Home/Pipeline/Lead Dry AMD Program

Lead Dry AMD Program

Dry Age-Related Macular Degeneration

PreclinicalActive

Key Facts

Indication
Dry Age-Related Macular Degeneration
Phase
Preclinical
Status
Active
Company

About Perceive Biotherapeutics

Perceive Biotherapeutics is a private, preclinical-stage biotech founded in 2021 and based in Cambridge, Massachusetts. The company is built upon exclusive access to foundational research on two of the strongest protective biological pathways in retinal degeneration. Led by a seasoned team with extensive experience in ophthalmology and drug development, Perceive Bio is advancing a diversified pipeline aimed at halting vision loss in conditions like dry AMD. The company is currently preparing its lead programs for clinical entry.

View full company profile

Other Dry Age-Related Macular Degeneration Drugs

DrugCompanyPhase
Dry-AMD High-Throughput ModelAxol BioscienceResearch/Preclinical Tools
elamipretide (ophthalmic)Stealth BioTherapeuticsPhase 3
Undisclosed PolyCol programStuart TherapeuticsPre-clinical